Last reviewed · How we verify
NaHCO3 Tablets
At a glance
| Generic name | NaHCO3 Tablets |
|---|---|
| Also known as | Baking soda |
| Sponsor | University of Texas at Austin |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Nausea
- Sinus tachycardia
- Diarrhoea
- Abdominal discomfort
- Pyrexia
- Chills
- Decreased appetite
- Vomiting
- Abdominal pain
- Haematochezia
- Oropharyngeal pain
Key clinical trials
- Role of Combination Therapy of Glucose Insulin Potassium Infusion (GIK), Intravenous Hydrocortisone and Oral Sevelamer in Treatment of Acute Aluminum Phosphide Poisoned Cases Admitted to Intensive Care Unit (ICU) at Sohag University Hospitals. (NA)
- Comparing Alkalinizing Agents Efficacy on Stone Risk in Patients on a Metabolically Controlled Diet (EARLY_PHASE1)
- Role of Preoperative Tapentadol in Reduction of Perioperative Analgesic Requirement After Breast Conservative Surgery in Cancer Patients. (NA)
- Neurovascular Regulation During Exercise in Humans With Chronic Kidney Disease: Sympatholysis in CKD (PHASE2)
- Reducing Dietary Acid With Food Versus Oral Alkali in People With Chronic Kidney Disease (ReDACKD) (NA)
- Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD (PHASE2)
- Exploratory Study on the Treatment of Gout With Potassium Citrate Sustained-release Tablets (PHASE4)
- Sympatholysis in Chronic Kidney Disease (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NaHCO3 Tablets CI brief — competitive landscape report
- NaHCO3 Tablets updates RSS · CI watch RSS
- University of Texas at Austin portfolio CI